Immunologic phenotype in 4 subgroups of patients withRAG deficiency
| . | T-B-SCID . | SCID with MFT . | Atypical SCID/OS . | OS . | Controls . |
|---|---|---|---|---|---|
| Lymphocytes (×103/μL) | 1.1 ± 0.5 | 3.2 ± 1.3 | 2.7 ± 1.0 | 7.2 ± 2.0 | 4.8 ± 0.35 |
| Eosinophils (×103/μL) | 0.18 ± 0.05 | 1.0 ± 0.4 | 2.28 ± 0.85 | 2.49 ± 0.47 | 0.25 ± 0.12 |
| CD3 (%) | 0.9 ± 0.5 | 23.9 ± 9.3 | 32.3 ± 7.2 | 65.4 ± 5.3 | 71.0 ± 6.0 |
| CD16 (%) | 72.9 ± 5.7 | 53.6 ± 8.2 | 48.5 ± 7.0 | 21.6 ± 5.3 | 11.0 ± 4.0 |
| CD19 (%) | 0.11 ± 0.11 | 0.43 ± 0.3 | 4.1 ± 1.5 | 1.9 ± 1.0 | 18.0 ± 5.0 |
| Response to PHA (cpm × 103) | 6.5 ± 2.4 | 15.5 ± 4.7 | 21.4 ± 10.1 | 13.4 ± 7.1 | 103.0 ± 15.0 |
| . | T-B-SCID . | SCID with MFT . | Atypical SCID/OS . | OS . | Controls . |
|---|---|---|---|---|---|
| Lymphocytes (×103/μL) | 1.1 ± 0.5 | 3.2 ± 1.3 | 2.7 ± 1.0 | 7.2 ± 2.0 | 4.8 ± 0.35 |
| Eosinophils (×103/μL) | 0.18 ± 0.05 | 1.0 ± 0.4 | 2.28 ± 0.85 | 2.49 ± 0.47 | 0.25 ± 0.12 |
| CD3 (%) | 0.9 ± 0.5 | 23.9 ± 9.3 | 32.3 ± 7.2 | 65.4 ± 5.3 | 71.0 ± 6.0 |
| CD16 (%) | 72.9 ± 5.7 | 53.6 ± 8.2 | 48.5 ± 7.0 | 21.6 ± 5.3 | 11.0 ± 4.0 |
| CD19 (%) | 0.11 ± 0.11 | 0.43 ± 0.3 | 4.1 ± 1.5 | 1.9 ± 1.0 | 18.0 ± 5.0 |
| Response to PHA (cpm × 103) | 6.5 ± 2.4 | 15.5 ± 4.7 | 21.4 ± 10.1 | 13.4 ± 7.1 | 103.0 ± 15.0 |
Values are expressed as mean ± SE.